AUTL News and Press, Autolus Therapeutics plc From 10/17/23

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to ...

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights befor...

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights befor...

2023-09-11 06:41:35 ET Summary Autolus is a UK-based CAR-T therapy developer with a lead program, obecabtagene autoleucel, that has met the endpoint in a pivotal trial for adult acute lymphoblastic leukemia. Obecabtagene autoleucel has a faster off-rate than other CAR-T therapies,...

2023-09-10 10:49:31 ET Summary Autolus Therapeutics develops T cell cancer therapies; "obe-cel" shows potential, with FDA submission expected by 2023 end. Financials indicate liquidity with $307.8M cash, but operational costs are depleting reserves; the company has about 23 months...

Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL Complete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Autolus Therap...

2023-08-06 07:59:05 ET Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Conference Call August 3, 2023, 8:30 a.m. ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Julia Wilson - IR Conference Call Par...

2023-08-03 07:11:09 ET Autolus Therapeutics press release ( NASDAQ: AUTL ): Q2 GAAP EPS of -$0.26 misses by $0.03 . Cash and cash equivalents and restricted cash at June 30, 2023, totaled $307.8 million, as compared to cash and cash equivalents and restricted cash of $...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Pivotal FELIX data at ASCO showed 76...

2023-08-02 14:04:22 ET Autolus Therapeutics ( NASDAQ: AUTL ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.22 (+52.2% Y/Y) and the consensus Revenue Estimate is $0.1M Over the last 3 months, ...